RB1 and neoplasm: Although patients with Rb-defective tumours (as defined by immunohistochemistry and/or gene expression) tend to have a relatively favourable response to classical chemotherapy [13–15] many either fail to respond to therapy or later relapse with therapy-resistant disease, suggesting that novel therapeutic approaches are required to target this patient subset.